Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate-associated neutropenia

AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic–pharmacodyn...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Hasselt, J G Coen, Gupta, Anubha, Hussein, Ziad, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2013
Assuntos:
Pharmacokinetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3769668/
https://ncbi.nlm.nih.gov/pubmed/23601153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados